ULTRAGENYX PHARMACEUTICAL

Lobbying client · California · filed 2025 to 2026

Biopharma company

$114,000 Reported spend

5 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 5 filings. Everything on this page is grouped by the client's LDA id (66778), not by name.

Firms hired 1

AVIVA STRATEGIES (FKA MGB CONSULTING) $114,000 5 filings

Reported by year 2 years

2026 $0 1 filing
2025 $114,000 4 filings

Issues lobbied 1

Health Issues 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

HOUSE OF REPRESENTATIVES 3
SENATE 3
Food & Drug Administration (FDA) 1

Recent filings 5 total

1T

AVIVA STRATEGIES (FKA MGB CONSULTING)

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 20, 2026

View → Q4

AVIVA STRATEGIES (FKA MGB CONSULTING)

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $38,000 income · posted Jan 15, 2026

View → Q3

AVIVA STRATEGIES (FKA MGB CONSULTING)

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $38,000 income · posted Oct 15, 2025

View → Q2

AVIVA STRATEGIES (FKA MGB CONSULTING)

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $38,000 income · posted Jul 16, 2025

View → RR

AVIVA STRATEGIES (FKA MGB CONSULTING)

2nd Quarter (Apr 1 - June 30) 2025 · posted May 24, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.